Expert Advice on Managing Severe Asthma

Released On
August 5, 2020

Expires On
August 4, 2021

Media Type
Internet

Completion Time
15 minutes

Specialty
Allergy & Immunology, Primary Care, Pulmonology

Topic(s)
Allergies, Asthma, Respiratory

Scroll to the Bottom of this Information to Begin this Course

Provided by Clinical Care Options, LLC.

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation, Sanofi Genzyme, and Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for allergists, immunologists, pulmonologists, primary care physicians, physician assistants, and other healthcare providers who care for patients with severe eosinophilic asthma.

Program Overview

The goal of this activity is to leverage a point-of-care tool along with expert commentary to improve the competence and performance of learners in diagnosing, assessing, and treating patients with severe eosinophilic asthma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select a biologic-based treatment strategy that targets the proinflammatory mechanisms of severe eosinophilic asthma
  • Describe the efficacy and safety of novel targeted biologic agents that have been recently approved as add-on therapy for severe eosinophilic asthma

Faculty

Michael E. Wechsler, MD, MMSc

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director
, NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP

President
Medical Director

Capital Allergy & Respiratory Disease Center
Sacramento, California

Nicola Alexander Hanania, MD, MS

Nicola Alexander Hanania, MD, MS

Associate Professor of Medicine
Department of Pulmonary and Critical Care Medicine
Baylor College of Medicine
Houston, Texas

Linda Rogers, MD

Linda Rogers, MD

Associate Professor of Medicine
Mount Sinai National Jewish Health Respiratory Institute
Icahn School of Medicine at Mount Sinai
Clinical Director, Adult Asthma Program
Division of Pulmonary, Critical Care, and Sleep Medicine
Department of Medicine
Mount Sinai Health System
New York, New York

Eileen Wang, MD, MPH

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physician Continuing Medical Education Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Faculty

Michael E. Wechsler, MD, MMSc, has disclosed that he has received funds for research support from AstraZeneca, Regeneron, Sanofi Genzyme, and Teva and consulting fees from AstraZeneca, Cohero, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, resTORbio, Sanofi Genzyme, and Teva.

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP, has disclosed that he has received consulting fees and fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron, and Sanofi Genzyme.

Nicola Alexander Hanania, MD, MS, has disclosed that he has received funds for research support from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, and Sanofi Genzyme; consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Mylan Novartis, and Sanofi Genzyme; and fees for non-CME/CE services from GlaxoSmithKline, Mylan, and Sanofi Genzyme.

Linda Rogers, MD, has disclosed that she has received funds for research support from AstraZeneca and Sanofi; consulting fees from AstraZeneca, Novartis, and Sanofi; and other financial or material support from AstraZeneca.

Eileen Wang, MD, MPH, has disclosed that she has received fees for non-CME/CE services from AstraZeneca and funds for research support from Genentech and GlaxoSmithKline.

Staff

Zachary Schwartz, MSc

Scientific Director
Zachary Schwartz, MSC, ELS, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Instructions for Participation and Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 05, 2020, through August 04, 2021:

  1. Register online at https://www.clinicaloptions.com.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

Contact Information

For CME questions please contact: skelley@clinicaloptions.com